OBJECTIVES/HYPOTHESIS: Epithelial-derived interleukin (IL)-33 and thymic stromal lymphopoietin (TSLP) are critical regulators of innate and adaptive immune responses associated with Th2 cytokine-mediated inflammation, including allergic rhinitis. IL-33 and TSLP are expressed not only in epithelial cells but also fibroblasts, endothelial cells, and smooth muscle cells at nasal mucosal sites. However, the role and the regulation of IL-33 and TSLP in nasal fibroblasts remain unknown. We investigated the signal transduction regulation of IL-33 and TSLP induced by proinflammatory cytokines in nasal fibroblasts. STUDY DESIGN: In vitro, prospective study. METHODS: Nasal fibroblasts were derived from human nasal mucosa without allergic rhinitis. Expression of IL-33 and TSLP was examined in nasal fibroblasts treated with proinflammatory cytokines IL-1β or tumor necrosis factor (TNF)-α after pretreatment with or without various inhibitors of signal transduction pathways. RESULTS: In nasal fibroblasts, both Western blotting and reverse transcriptase-polymerase chain reaction demonstrated that expression of mRNAs and proteins of IL-33 and TSLP was increased by treatment with IL-1β or TNF-α. Immunostaining revealed that IL-33-positive nuclei were markedly increased by the treatment with IL-1β or TNF-α. Enzyme-linked immunosorbent assay showed that fibroblast-released TSLP was significantly increased by treatment with IL-1β or TNF-α. The upregulation of both IL-33 and TSLP proteins by treatment with IL-1β was prevented by inhibitors of pan- protein kinase C (PKC), p38 mitogen-activated protein kinase, and nuclear factor (NF)-κB. In the cells treated with TNF-α, upregulation of IL-33 protein was prevented by inhibitors of phosphoinositide 3-kinase (PI3K), c-Jun N-terminal kinase (JNK), and NF-κB, whereas upregulation of TSLP protein was prevented by inhibitors of pan-PKC, PI3K, JNK, and NF-κB. CONCLUSIONS: Expression of IL-33 and TSLP in nasal fibroblasts was regulated via distinct signal transduction pathways including NF-κB.
OBJECTIVES/HYPOTHESIS: Epithelial-derived interleukin (IL)-33 and thymic stromal lymphopoietin (TSLP) are critical regulators of innate and adaptive immune responses associated with Th2 cytokine-mediated inflammation, including allergic rhinitis. IL-33 and TSLP are expressed not only in epithelial cells but also fibroblasts, endothelial cells, and smooth muscle cells at nasal mucosal sites. However, the role and the regulation of IL-33 and TSLP in nasal fibroblasts remain unknown. We investigated the signal transduction regulation of IL-33 and TSLP induced by proinflammatory cytokines in nasal fibroblasts. STUDY DESIGN: In vitro, prospective study. METHODS: Nasal fibroblasts were derived from human nasal mucosa without allergic rhinitis. Expression of IL-33 and TSLP was examined in nasal fibroblasts treated with proinflammatory cytokines IL-1β or tumor necrosis factor (TNF)-α after pretreatment with or without various inhibitors of signal transduction pathways. RESULTS: In nasal fibroblasts, both Western blotting and reverse transcriptase-polymerase chain reaction demonstrated that expression of mRNAs and proteins of IL-33 and TSLP was increased by treatment with IL-1β or TNF-α. Immunostaining revealed that IL-33-positive nuclei were markedly increased by the treatment with IL-1β or TNF-α. Enzyme-linked immunosorbent assay showed that fibroblast-released TSLP was significantly increased by treatment with IL-1β or TNF-α. The upregulation of both IL-33 and TSLP proteins by treatment with IL-1β was prevented by inhibitors of pan- protein kinase C (PKC), p38 mitogen-activated protein kinase, and nuclear factor (NF)-κB. In the cells treated with TNF-α, upregulation of IL-33 protein was prevented by inhibitors of phosphoinositide 3-kinase (PI3K), c-Jun N-terminal kinase (JNK), and NF-κB, whereas upregulation of TSLP protein was prevented by inhibitors of pan-PKC, PI3K, JNK, and NF-κB. CONCLUSIONS: Expression of IL-33 and TSLP in nasal fibroblasts was regulated via distinct signal transduction pathways including NF-κB.
Authors: L Bjerkan; O Schreurs; S A Engen; F L Jahnsen; E S Baekkevold; I J S Blix; K Schenck Journal: Mucosal Immunol Date: 2014-05-21 Impact factor: 7.313
Authors: Luan D Vu; Anh T Q Phan; Diego R Hijano; David T Siefker; Heather Tillman; Stephania A Cormier Journal: Am J Respir Cell Mol Biol Date: 2022-03 Impact factor: 6.914
Authors: Ishan Goswami; Sheryl Coutermarsh-Ott; Ryan G Morrison; Irving C Allen; Rafael V Davalos; Scott S Verbridge; Lissett R Bickford Journal: Bioelectrochemistry Date: 2016-09-25 Impact factor: 5.373
Authors: D Kaur; E Gomez; C Doe; R Berair; L Woodman; R Saunders; F Hollins; F R Rose; Y Amrani; R May; J Kearley; A Humbles; E S Cohen; C E Brightling Journal: Allergy Date: 2015-03-16 Impact factor: 13.146